Objective:

To evaluate the long-term safety and efficacy of the Hydrus® Microstent in reducing intraocular pressure (IOP) and medication usage in glaucoma patients.

Key Findings:

• 80% of patients completed a full five-year follow-up.
• 77.2% of Hydrus patients achieved an unmedicated IOP reduction of ≥20% from baseline at 24 months.
• 59% of Hydrus patients remained entirely medication-free at five years.
• Hydrus reduced day-one postoperative IOP spikes to 1.4% compared to 14.4% in the control group.
• Fewer patients in the Hydrus group required later incisional glaucoma surgery.

Interpretation:

The long-term data from the HORIZON study demonstrates the Hydrus Microstent's effectiveness in managing glaucoma, reducing the need for medications and additional surgeries, while also minimizing postoperative IOP spikes.

Limitations:

• The study may have selection bias due to the specific patient population.
• Long-term outcomes beyond five years are still unknown.

Conclusion:

The Hydrus Microstent shows promising long-term results in managing glaucoma, offering significant benefits in IOP control and medication reduction, which can enhance patient quality of life.